New Logo.png
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
May 02, 2024 08:00 ET | Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has...
1519461323.png
Guangzhou Bio-gene Technologies Announces Initiation of Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1
May 02, 2024 07:30 ET | Bio-Gene Technology Co Ltd
Guangzhou Bio-gene Technologies announces the Initiation of a Phase I Clinical Trial for BG1805, a CAR-T Targeting CLL-1 in patients with AML
Bionano_RGB.png
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
April 24, 2024 08:00 ET | Bionano Genomics
Researchers used Cas9-directed Nanopore sequencing to validate structural variants detected by optical genome mapping in leukemia samples.
Bionano_RGB.png
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
April 11, 2024 08:00 ET | Bionano Genomics
Researchers used optical genome mapping in addition to whole genome sequencing in pediatric leukemia samples and identified additional structural variants.
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio to Participate in Upcoming Investor Conferences
April 01, 2024 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...
cmi_logo.png
[Latest] Global Cancer Immunotherapy Market Size/Share Worth USD 314.4 Billion by 2032 at a 7.2% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
March 28, 2024 15:30 ET | Custom Market Insights
Austin, TX, USA, March 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Cancer Immunotherapy Market Size, Trends and Insights By Type of Immunotherapy...
22157.jpg
2024 KOL Interview on Acute Myeloid Leukemia (AML) Treatment in Southern US: Expert Insights and Emerging Therapies - Magrolimab, Quizartinib, Crenolanib, Gilteritinib, and Uproleselan
March 21, 2024 05:49 ET | Research and Markets
Dublin, March 21, 2024 (GLOBE NEWSWIRE) -- The "Acute Myeloid Leukemia (AML) KOL Interview - US, South" report has been added to ResearchAndMarkets.com's offering. This report presents an...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
March 20, 2024 16:05 ET | Vor Biopharma
Trem-cel and VCAR33ALLO clinical trial data expected in the second half of 2024VCAR33ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into...
Kura Oncology Logo
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 16:01 ET | Kura Oncology, Inc.
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008...
NMDP BioTherapies
NMDP BioTherapies Appoints New President to Lead Next Phase in Life-Saving Therapy Development
January 30, 2024 09:00 ET | NMDP
NMDP BioTherapies℠, formerly Be The Match BioTherapies, announced that Tom Hochuli will serve as president.